BIOX Earnings Prediction
The chart below shows how BIOX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BIOX sees a +7.60% change in stock price 10 days leading up to the earnings, and a +1.90% change 10 days following the report. On the earnings day itself, the stock moves by -1.28%. This data can give you a slight idea of what to expect for the next quarter's release.
BIOX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
140.29M
50.79%
20.75%
Gross Margin
36.77%
0.93%
-4.14%
Operating Margin
11.13%
346.99%
168.19%
Net Margin
0.88%
109.71%
-138.10%
EPS
0.00
-100.00%
-100.00%
No Data Available
BIOX Earnings Analysis
Bioceres Crop Solutions Corp Corporation (BIOX.O) Earnings Conference Call
Positive
Gross Margin Improvement: Gross margin expanded from 37% to 42% during the quarter, indicating improved profitability despite a revenue decline.
Market Share Resilience: Despite a challenging market in Argentina, key product families maintained or expanded market share, demonstrating resilience in core offerings.
Geographic Diversification Success: Sales outside of Argentina grew during the first half, reflecting the success of the geographic diversification strategy.
Corporate Nutrition Gross Profit Growth: Gross profit for the Corporate Nutrition segment increased by 6%, driven by strong performance in high-margin inoculants, leading to a gross margin expansion to 57%.
Leadership Appointment Impact: The appointment of Milen Marinov as Chief Commercial Officer is expected to accelerate profitable growth and streamline commercial operations.
Negative
Revenue Decline Analysis: Revenues declined by 24% year-over-year, totaling $106 million, primarily due to poor performance in Argentina, which is critical for the company's financial health.
Crop Protection Revenue Decline: Crop protection revenues fell from $71 million to just above $55 million, a 29% drop attributed to lower sales in Argentina, aligning with a 27% contraction in the overall crop protection sector.
EBITDA Decline Analysis: Adjusted EBITDA decreased to $15.4 million from approximately $24 million in the previous year, driven by reduced gross profit in crop protection and increased SG&A expenses, particularly in Argentina.
Increased Financial Leverage: Net debt increased by $26 million to $238 million, resulting in a leverage ratio of 3.3 turns, surpassing the target threshold of three turns, indicating increased financial risk.
Gross Profit Decline: Gross profit for the quarter was $45 million, reflecting a 12% decline, with crop protection and microgrid fertilizers being the main contributors to this drop.
BIOX FAQs
How does BIOX typically perform around its earnings report dates?
Is Bioceres Crop Solutions Corp (BIOX) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BIOX Earning Call Sentiment
Earnings call transcript: Bioceres Crop Solutions misses Q2 2024 forecasts
BIOX.O
-4.1%Positive
The earnings call presents mixed signals. While gross margin improved and inventory management tightened, overall revenues declined significantly, and net debt increased. The strategic shift in the seed business and partnerships may benefit long-term profitability but pose short-term uncertainties. The Q&A highlighted potential positive impacts from partnerships but lacked specific financial details, causing some analyst concern. Given these factors, the short-term stock price is likely to remain stable, falling within the neutral range.
